Related references
Note: Only part of the references are listed.Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).
N. B. Leighl et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
R. Bianco et al.
BRITISH JOURNAL OF CANCER (2008)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression
Marie-Emmanuelle Legrier et al.
CANCER RESEARCH (2007)
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
Bruce E. Johnson et al.
CLINICAL CANCER RESEARCH (2007)
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells
Tianhong Li et al.
CLINICAL CANCER RESEARCH (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T. Haritunians et al.
LEUKEMIA (2007)
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
Cataldo Bianco et al.
CLINICAL CANCER RESEARCH (2006)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway
Piotr Smolewski
ANTI-CANCER DRUGS (2006)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
T Mukohara et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
F Koizumi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
BR Balsara et al.
CARCINOGENESIS (2004)
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):: Superiority over single-agent receptor targeting
P Matar et al.
CLINICAL CANCER RESEARCH (2004)
Regulation of translation initiation by FRAP/mTOR
AC Gingras et al.
GENES & DEVELOPMENT (2001)